Boston biotech Albireo Pharma has won FDA approval for Bylvay (odevixibat), the first drug approved for the treatment of a rare liver disease called progressive familial intrahepatic cholestasis or PFIC. PFIC is a rare and devastating disorder affecting young children that causes progressive, life-threatening liver disease. In many cases, PFIC leads to cirrhosis and liver […]

Cambridge-based Amylyx Pharmaceuticals has closed a $135 million Series C financing to support the clinical development and potential launch plans for lead product candidate AMX0035, for the potential treatment of ALS, and further research and development in other neurodegenerative diseases. The financing was led by Viking Global Investors with participation from Bain Capital Life Sciences […]

Cambridge-based microbiome therapeutics company Seres Therapeutics has entered into an agreement with Nestlé Health Science to jointly commercialize SER-109, Seres’ investigational oral microbiome therapeutic for recurrent Clostridioides difficile infection (CDI), in the U.S. and Canada. If approved, SER-109 would become the first-ever FDA-approved microbiome therapeutic. Under the terms of the agreement, Nestlé Health Science will utilize its global pharmaceutical business […]

Cambridge-based venture capital company Flagship Pioneering has raised an additional $2.23 billion for a total capital pool of $3.37 billion. This brings together for the first time its origination and growth strategies under one investment vehicle with a long-term focus on the creation, development, and growth of its first-in-category bioplatform companies. “We are grateful to […]

Sanofi has announced it will invest approximately $475 million annually in a first-of-its kind two-site mRNA vaccines Center of Excellence in Cambridge, MA and Lyon, France. The Center will work to accelerate the development and delivery of next-generation vaccines by bringing together approximately 400 dedicated employees integrating end-to-end mRNA vaccine capabilities including dedicated R&D, manufacturing […]

Boston-based Valo Health has entered into a definitive merger agreement with Khosla Ventures Acquisition Co. (KVAC), a special purpose acquisition company or SPAC. The transaction represents a pro forma market value of approximately $2.8 billion for the combined company. Valo anticipates the pro forma cash balance of the combined company will be approximately $750 million before expenses. Founded by Flagship Pioneering, Valo has built an internal pipeline with two […]